1. After oral administration of acetylruthenocene to rats, metabolites were detected in bile and urine. 2. The major metabolite, which is present in both bile and urine, is a glucuronide with the structure:
Previous studies in this laboratory (Wenzel et al., 1976 showed that ruthenocene derivatives labelled with 103Ru could be useful as radioactive diagnostic agents. One of these compounds, acetyl-
[103Ru]ruthenocene (structure shown below), showed an affinity for adrenal glands. As part of a study to determine how and in what form the radioactivity accumulates in adrenals, the major metabolite of acetylruthenocene was isolated from urine and subsequently identified.
1/tCO-CH3 Ru Acetylruthenocene
The metabolism of the benzene analogue of acetylruthenocene, acetophenone, has been extensively studied (see Kiese & Lenk, 1974 , for a review) and both major and minor metabolites have been identified. The major metabolites formed are: * Present address and address for reprints: Department of Applied Biochemistry and Nutrition, University of Nottingham School of Agriculture, Sutton Bonington, Loughborough LE12 5RD, Leics., U.K. Vol. 172 (1) a glucuronide or sulphate conjugate produced after reduction of the keto group; (2) a hippuric acid conjugate formed after oxidation of the methyl group and decarboxylation (Thierfelder & Daiber, 1923; Thierfelder & Klenk, 1924) . Traces of ringhydroxylated m-and p-acetophenone were also detected, as well as small amounts of mandelic acid.
Since we showed that the parent compound ruthenocene is metabolized in vivo by the same pathway as is benzene (Taylor & Wenzel, 1977 , 1978 , it seemed likely that acetylruthenocene would follow the degradative scheme for acetophenone as far as the extra bulk of the cyclopentadiene metal 'sandwich' structure would allow.
Experimental and Results Preparation ofacetylruthenocene
Acetylruthenocene was prepared by FriedelCrafts acylation of ruthenocene (Serva, Heidelberg, Germany). Ruthenocene (2.3 g, 0.01 mol) was dissolved in redistilled, dry methylene chloride and stirred while anhydrous AIC13 (2.7g, 0.02mol) was added. After 15min at room temperature (20°C), the complex was refluxed (about 40°C) and redistilled acetyl chloride (0.8 g, 0.01 mol) was added in a dropwise manner. Reflux continued for 1.5 h. On cooling, the complex was destroyed with ice/water, and ascorbic acid was added until the layers cleared. They were then extracted with diethyl ether. The pooled ether extracts were washed, dried over anhydrous MgSO4 and ether was removed in vacuo.
The reaction products were separated by applying portions of the crude product (dissolved in benzene) (Langheim et al., 1975) . The reaction products were dissolved in benzene, and labelled acetylruthenocene was separated from other radioactive products on thin-layer silica-gel plates in solvent A as described by Langheirnvet al. (1975) .
Radiochromatography
103Ru-labelled compounds were located and determined by measuring the ,6-and Auger-electrons of 103Ru (Wenzel & Abdul-Wahid, 1975 ) on a thinlayer scanner (Berthold, Wildbad, Germany).
Preparation ofa solution ofacetyiruthenocene
Unlabelled acetylruthenocene (100-150mg) was mixed with the radioactive compound (approx.
1.5puCi) and dissolved in propylene glycol (2ml).

Metabolism experiments
Three female adult Wistar rats (200-250g; Hagemann, 4923 Extertal, Germany) received orally 30-50mg of the radioactive acetylruthenocene mixture in propylene glycol (max. vol. 1 ml). They were placed in metabolism cages, and urine and faeces were collected. A layer of toluene was placed in the urine-collecting vessels. Samples were collected daily for 4 days after administration of acetylruthenocene, and the amount of radioactivity in toluene, urine and faeces was determined by counting the samples in the well of a Nal-crystal y-counter (Berthold, Wildbad, Germany). At 90h after administration, urine contained 54% of the administered radioactivity, faeces 28% and the toluene extract of urine 2% (values obtained from pooled samples).
Extraction and identification of the major metabolite (glucuronide)
The urine obtained over a 4-day period after oral administration of acetylruthenocene was stored frozen at -20°C and thawed when required. T.l.c. of a portion in butan-1-ol/acetic acid/water (4:1:1, by vol.) (solvent B) showed two radioactive components, a major one at RF 0.48 and a minor one at RF 0.72. Separation and analysis of the metabolites was as follows.
(1) Portions (1Oml) of urine were chromatographed on a column (10cmxlcm) of Amberlite XAD-2 (Serva, Heidelberg, Germany) by the method of Bradlow (1968) . The methanol eluate contained approx. 70% of the applied radioactivity, and t.l.c. of a portion showed two peaks in solvent B on silicagel plates [typical RF values 0.44 (major) and 0.68 (minor); the major component accounted for 91 % of applied radioactivity, the minor, 9 %].
(2) A portion of the methanol extract was divided into three equal samples that were evaporated to dryness and then dissolved in 0.5 ml of 0.1 M-sodium acetate buffer, pH 4.5. Penicillin (500i.u./ml; Hoechst A.G., Frankfurt, Germany) was added to each to prevent bacterial growth during the 24-h incubation period. The test incubation contained fl-glucuronidase [0.09 unit (,umol/min)/ml; ox liver; Serva] and the control incubation mixtures contained either boiled enzyme or no enzyme. After 24h at 37°C, portions of the incubates were chromatographed on thin-layer plates in solvent B and radioautograms prepared. The major metabolite was completely converted by fi-glucuronidase into a component ofRF value 0.9-1.0.
The minor component was only partially converted. With the control incubates there was no conversion of the major or minor components into secondary products. The test incubation mixture was extracted with toluene, the extract was concentrated in vacuo and chromatographed on thin-layer plates in solvent A, which produced a single radioactive peak at RF 0.4. Further t.l.c. proved that the aglycone formed by hydrolysis with ,B-glucuronidase was identical with the component extracted with toluene from urine.
(3) The remaining methanol extracts from the Amberlite XAD-2 column were pooled, concentrated and chromatographed on thin-layer plates in solvent B by using prewashed plates and redistilled solvents. After three purifications on t.l.c., 8mg of the major metabolite (RF 0.44-0.48) were obtained. The repeated chromatography of the minor metabolite caused degradation, and the amounts recovered were insufficient for analysis. The purified major meta-1978 Leclerq & Desiderio (1971) . The sample was dissolved in 800,p of redistilled dry dimethyl sulphoxide, flushed with N2, treated with the sodium salt of dimethyl sulphoxide for 15 min and then 150,ul ofmethyl iodide was added. After 1.5h at room temperature, 1.5 ml of water was added, the mixture was extracted with 4 x 1 ml of chloroform, the extracts were pooled, washed with water, dried over anhydrous MgSO4, and chloroform was removed in vacuo. Mass spectrometry of the sample (with a Varian MAT CH-7A instrument with an EI/FD ion source operating at 200°C and 70eV) gave the spectrum in Fig. l(a) . The interpretation of the spectrum is discussed below.
(5) Another portion of the purified metabolite was hydrolysed with ,6-glucuronidase under the same conditions as described in paragraph (2). After 24h, the solution was extracted with redistilled toluene, then another 0.09 unit of enzyme was added/ml and at 48 h the solution was again extracted with toluene. Fig. 2(a) and mass spectrometry at 70°C and 70eV produced the spectrum in Fig. l(b) . The spectra are discussed in the next section.
Biliary excretion ofmetabolites
Two rats were anaesthetized and fitted withjugularvein and bile-duct cannulae. Anaesthesia was maintained by administering Nembutal (Deutsche Abbott, Ingelheim am Rhein, Germany) through the jugularvein cannulae. A solution of acetylruthenocene (1 50ul; llmg/kg) in propylene glycol was also administered via the jugular vein, and bile samples were collected every hour for 6h. In the 6-h period, between 43 and 70 % of the dose was excreted in bile. T.l.c. of the bile in solvent B, and of a chloroform extract of bile in solvent A, showed that the bile contained a major metabolite that was chromatographically identical with the major metabolite in urine. The chloroform extract contained small amounts of the aglycone and smaller amounts of unchanged acetylruthenocene. Hydrolysis of the major metabolite in bile with f?-glucuronidase and The strong signal at 2.29p.p.m., corresponding to the methyl protons of acetylruthenocene, is missing from the aglycone spectrum, showing that the molecule is hydroxylated on the methyl group and not in the rings.
1978 comparison by t.l.c. of the aglycones in bile and urine showed that they were identical.
Discussion
The results show that after oral administration of acetylruthenocene to rats, urine contains a glucuronide as the major metabolite, another metabolite that appears unstable under the purification procedure, and small amounts of the aglycone of the major metabolite.
Identification of the major metabolite as a glucuronide allowed us to formulate possible structures for the compound. If Rc-CO-CH3 -* Rc-CO-CH2-OH Rc-CO-CH2-O-glucuronide Acetophenone, however, is metabolized mainly by reduction of the keto group and conjugation of the secondary alcohol so formed with glucuronic acid or sulphate. A secondary pathway of acetophenone metabolism involves degradation of the side chain to give benzoic acid, which is excreted as its glycine conjugate, hippuric acid (for a review, see Kiese & Lenk, 1974) .
Therefore acetylruthenocene does not produce the pattern of metabolism observed with acetophenone. It seems that the extra bulk of the aromatic cyclopentadiene metal sandwich structure prevents reduction of the keto group to the extent seen with acetophenone. Instead, the methyl group of acetylruthenocene is oxidized to a primary alcohol that is conjugated with glucuronic acid. Whether or not the unidentified minor metabolite is a glycine conjugate of a carboxylic acid arising from further metabolism of this primary alcohol remains to be determined.
